Literature DB >> 21709263

Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cells.

Ying-Chih Liu1, Hsin-Yung Yen, Chien-Yu Chen, Chein-Hung Chen, Ping-Fu Cheng, Yi-Hsiu Juan, Chung-Hsuan Chen, Kay-Hooi Khoo, Chong-Jen Yu, Pan-Chyr Yang, Tsui-Ling Hsu, Chi-Huey Wong.   

Abstract

Protein glycosylation is an important posttranslational process, which regulates protein folding and functional expression. Studies have shown that abnormal glycosylation in tumor cells affects cancer progression and malignancy. In the current study, we have identified sialylated proteins using an alkynyl sugar probe in two different lung cancer cell lines, CL1-0 and CL1-5 with distinct invasiveness derived from the same parental cell line. Among the identified sialylated proteins, epidermal growth factor receptor (EGFR) was chosen to understand the effect of sialylation on its function. We have determined the differences in glycan sequences of EGFR in both cells and observed higher sialylation and fucosylation of EGFR in CL1-5 than in CL1-0. Further study suggested that overexpression of sialyltransferases in CL1-5 and α1,3-fucosyltransferases (FUT4 or FUT6) in CL1-5 and A549 cells would suppress EGFR dimerization and phosphorylation upon EGF treatment, as compared to the control and CL1-0 cells. Such modulating effects on EGFR dimerization were further confirmed by sialidase or fucosidase treatment. Thus, increasing sialylation and fucosylation could attenuate EGFR-mediated invasion of lung cancer cells. However, incorporation of the core fucose by α1,6-fucosylatransferase (FUT8) would promote EGFR dimerization and phosphorylation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21709263      PMCID: PMC3136320          DOI: 10.1073/pnas.1107385108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

1.  Overexpression of fucosyltransferase IV promotes A431 cell proliferation through activating MAPK and PI3K/Akt signaling pathways.

Authors:  Xue-Song Yang; Shuai Liu; Yue-Jian Liu; Ji-Wei Liu; Ting-Jiao Liu; Xiao-Qi Wang; Qiu Yan
Journal:  J Cell Physiol       Date:  2010-11       Impact factor: 6.384

Review 2.  Mining the plasma proteome for cancer biomarkers.

Authors:  Samir M Hanash; Sharon J Pitteri; Vitor M Faca
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

3.  Beta1,6-N-acetylglucosamine-bearing N-glycans in human gliomas: implications for a role in regulating invasivity.

Authors:  H Yamamoto; J Swoger; S Greene; T Saito; J Hurh; C Sweeley; J Leestma; E Mkrdichian; L Cerullo; A Nishikawa; Y Ihara; N Taniguchi; J R Moskal
Journal:  Cancer Res       Date:  2000-01-01       Impact factor: 12.701

4.  Overexpression of ST6GalNAcV, a ganglioside-specific alpha2,6-sialyltransferase, inhibits glioma growth in vivo.

Authors:  Roger A Kroes; Huan He; Mark R Emmett; Carol L Nilsson; Franklin E Leach; I Jonathan Amster; Alan G Marshall; Joseph R Moskal
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

5.  Characterization of the carbohydrate chains of the secreted form of the human epidermal growth factor receptor.

Authors:  C J Stroop; W Weber; G J Gerwig; M Nimtz; J P Kamerling; J F Vliegenthart
Journal:  Glycobiology       Date:  2000-09       Impact factor: 4.313

Review 6.  Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis.

Authors:  Reiji Kannagi; Mineko Izawa; Tetsufumi Koike; Keiko Miyazaki; Naoko Kimura
Journal:  Cancer Sci       Date:  2004-05       Impact factor: 6.716

7.  Glycans on influenza hemagglutinin affect receptor binding and immune response.

Authors:  Cheng-Chi Wang; Juine-Ruey Chen; Yung-Chieh Tseng; Che-Hsiung Hsu; Yu-Fu Hung; Shih-Wei Chen; Chin-Mei Chen; Kay-Hooi Khoo; Ting-Jen Cheng; Yih-Shyun E Cheng; Jia-Tsrong Jan; Chung-Yi Wu; Che Ma; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-12       Impact factor: 11.205

Review 8.  Ligand-induced ErbB receptor dimerization.

Authors:  Mark A Lemmon
Journal:  Exp Cell Res       Date:  2008-10-31       Impact factor: 3.905

9.  The oligosaccharide moieties of the epidermal growth factor receptor in A-431 cells. Presence of complex-type N-linked chains that contain terminal N-acetylgalactosamine residues.

Authors:  R D Cummings; A M Soderquist; G Carpenter
Journal:  J Biol Chem       Date:  1985-10-05       Impact factor: 5.157

10.  N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor.

Authors:  Kazuko Matsumoto; Hideyuki Yokote; Tokuzo Arao; Mari Maegawa; Kaoru Tanaka; Yoshihiko Fujita; Chikako Shimizu; Toshiaki Hanafusa; Yasuhiro Fujiwara; Kazuto Nishio
Journal:  Cancer Sci       Date:  2008-08       Impact factor: 6.716

View more
  147 in total

1.  Visualizing specific protein glycoforms by transmembrane fluorescence resonance energy transfer.

Authors:  Yoshimi Haga; Kumiko Ishii; Kayo Hibino; Yasushi Sako; Yukishige Ito; Naoyuki Taniguchi; Tadashi Suzuki
Journal:  Nat Commun       Date:  2012-06-19       Impact factor: 14.919

2.  Enhanced N-glycosylation site exploitation of sialoglycopeptides by peptide IPG-IEF assisted TiO2 chromatography.

Authors:  Weiqian Cao; Jing Cao; Jiangming Huang; Lei Zhang; Jun Yao; Haoqi Xu; Pengyuan Yang
Journal:  Glycoconj J       Date:  2012-07-08       Impact factor: 2.916

Review 3.  Application of glycoproteomics for the discovery of biomarkers in lung cancer.

Authors:  Qing Kay Li; Edward Gabrielson; Hui Zhang
Journal:  Proteomics Clin Appl       Date:  2012-06       Impact factor: 3.494

Review 4.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

5.  The Glycosyltransferase ST6Gal-I Protects Tumor Cells against Serum Growth Factor Withdrawal by Enhancing Survival Signaling and Proliferative Potential.

Authors:  Colleen M Britain; Kaitlyn A Dorsett; Susan L Bellis
Journal:  J Biol Chem       Date:  2017-01-30       Impact factor: 5.157

6.  Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.

Authors:  Hsin-Yung Yen; Ying-Chih Liu; Nai-Yu Chen; Chia-Feng Tsai; Yi-Ting Wang; Yu-Ju Chen; Tsui-Ling Hsu; Pan-Chyr Yang; Chi-Huey Wong
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-13       Impact factor: 11.205

7.  Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.

Authors:  Motoko Takahashi; Yoshihiro Hasegawa; Yoshitaka Ikeda; Yoshinao Wada; Michiko Tajiri; Shigeru Ariki; Rina Takamiya; Chiaki Nishitani; Motoko Araki; Yoshiki Yamaguchi; Naoyuki Taniguchi; Yoshio Kuroki
Journal:  J Biol Chem       Date:  2013-10-04       Impact factor: 5.157

8.  A novel method for the simultaneous enrichment, identification, and quantification of phosphopeptides and sialylated glycopeptides applied to a temporal profile of mouse brain development.

Authors:  Giuseppe Palmisano; Benjamin L Parker; Kasper Engholm-Keller; Sara Eun Lendal; Katarzyna Kulej; Melanie Schulz; Veit Schwämmle; Mark E Graham; Henrik Saxtorph; Stuart J Cordwell; Martin R Larsen
Journal:  Mol Cell Proteomics       Date:  2012-07-26       Impact factor: 5.911

9.  Lewis y antigen is expressed in oral squamous cell carcinoma cell lines and tissues, but disappears in the invasive regions leading to the enhanced malignant properties irrespective of sialyl-Lewis x.

Authors:  Hiroshi Hotta; Kazunori Hamamura; Kyoko Yamashita; Hidenobu Shibuya; Noriyo Tokuda; Noboru Hashimoto; Keiko Furukawa; Noriyuki Yamamoto; Hisashi Hattori; Shinya Toyokuni; Minoru Ueda; Koichi Furukawa
Journal:  Glycoconj J       Date:  2012-12-15       Impact factor: 2.916

Review 10.  Glycosylation in cancer: mechanisms and clinical implications.

Authors:  Salomé S Pinho; Celso A Reis
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.